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Objectives
FMF is the most common autoinflammatory disease char-
acterized by recurrent febrile polyserositis. The gravest
consequence of FMF is nephropatic amyloidosis of AA
type, which may progress to affect other organs, including
the lungs[1]. Pulmonary hypertension (PH) in FMF related
amyloidosis is rare; only a few cases have been reported so
far[2,3]. We aim to elucidate development of PH in FMF in
Armenian patients group.
Methods
80 FMF patients without amyloidosis (mean age 33.6±11.8,
male/female 45/35) and 75 FMF-amyloidosis patients
(37.8±7.4, 42/33) were included in the study and followed
prospectively for 3 years. All patients had recurrent pleuri-
tis except of three phenotype II patients. Selected patients
were homo/heterozygous for the M694V(n=122), M680I
(28), V726A(4) and E148Q(1) mutations. Chest X-ray,
pulmonary function test, ECG, transthoracic Doppler
echocardiography (TTE) and CT-scan were carried out.
Hb, ESR, leucocytes, fibrinogen, CRP, SAA, creatinine and
capillary blood gases were measured. All patients were
attack-free under colchicine treatment at the time of the
study except of two hemodialysis patients. We considered
patients to have PH if their estimated pulmonary artery
systolic pressure (PASP) was >35 mm Hg as measured by
TTE.
Results
(6%) FMF patients without amyloidosis and 9 (12%) with
amyloidosis were diagnosed having PH (male/female 5/9).
The median age at the diagnosis of PH was 48 years (range,
36-72). The median FMF duration at the time of PH diag-
nosis was 36 (1-60) years. All patients had symptoms
related to PH: exertional dyspnea and fatigue (14 patients),
chest pain (10), hepatomegaly (7), anorexia and weight loss
(7), peripheral edema (6), ascites (5), cough (3), palpitation
(3) and syncope (1). 4 patients had palpable right ventricu-
lar lift and 6 had increased intensity of P2 or splitting of S2.
TTE data were as following: the median ejection fraction
was 50% (20-60), the median PASP was 40 mm Hg (36-64).
9 patients had right ventricular dilatation and/or hypertro-
phy, tricuspid regurgitation of different degree, and 3
patients had pericardial effusion (90, 120, 150ml). Chest
X-ray findings were abnormal in 11 patients (9 FMF-amy-
loidosis and 2 without amyloidosis) and showed opacities,
hilar adenopathy, pleural thickening and pleural effusion.
The other 3 patients had pleural adhesions. Chest CT scans
findings were suggestive for cardiac and pulmonary amyloi-
dosis (interstitial reticulonodular infiltrates) in 8 patients.
PFT revealed restrictive pattern in 10 patients, restriction
with mild obstruction in 2 patients and lung volumes were
normal in 1 patient without amyloidosis.
Patients were not treated for their PH. Three patients
died of cardiac complications (congestive heart failure),
they had impaired kidney function as well, and one amy-
loidosis patient died because of uremia. On autopsy amy-
loid deposits in kidney, spleen, liver, heart and lungs were
found in three cases. The median time to death after the
diagnosis of PH was 470 days (range 135-1095).
Lab tests were as following in FMF-amyloidosis patients
group vs group without it (mean±SD): CRP 17.74±13.74
mg/L vs 11,88±13.79 mg/L and SAA 33±66.6 mg/L vs
5.25±4,45mg/L (p<0,0001). PO283.6±8.95 mmHg,
PCO239.4±3.6 mmHg, O2Sat 94.6±3.38% vs. PO274±11.36,
PCO235.3±4.5, O2Sat 90.1±10.26% (P<0.0001).
Conclusions
Patients with FMF may develop PH late in the disease pro-
cess with resultant right-sided heart failure. The prognosis
of AA amyloidosis depends on the degree of renal dys-
function at presentation and whether the underlying1Yerevan State Medical University, Internal Medicine, Yerevan, Armenia
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inflammatory disease can be effectively suppressed[4]. We
speculate that PH in FMF is a consequence of ongoing
inflammation and amyloidosis with subsequent early vas-
cular alteration. This may explain PH development in the
absence of severe intravascular amyloid deposits. PH
develops in most untreated patients and in those who are
on hemodialysis. In published case reports[2,3] the prog-
nosis of FMF patients with PH and amyloidosis was poor.
Our data are in accordance with them; PH in FMF may
have a fatal course. We conclude that PH should be con-
sidered in FMF patients with dyspnea, fatigue or fluid
overload, especially in individuals with amyloidosis. If pre-
sent, PH should be monitored and treated.
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